肌层浸润性膀胱癌(Muscle-Invasive Bladder Cancer,MIBC)是指临床分期为T2~T4的膀胱癌。具有进展快,易复发,易远处转移,恶性程度高,病死率高等特点。MIBC的标准治疗方法是根治性膀胱切除术(Radical Cystectomy,RC)同时行盆腔淋巴结清扫术(Pelvic Lymph Node Dissection,PLND),但是术后患者5年生存率只有27%~67%。我国指南已经推荐将以顺铂为基础的新辅助化疗作为MIBC的一线治疗方案。新辅助化疗则可以提高MIBC患者的5年生存率。现对新辅助化疗的化疗方案、现状以及研究方向等方面进行综述。 Muscle-Invasive Bladder Cancer (MIBC) refers to bladder cancer with clinical stage T2-T4. With rapid progress, easy to relapse, distant metastasis, high degree of malignancy, high mortality. The standard treatment for MIBC is Radical Cystectomy (RC) with Pelvic Lymph Node Dissection (PLND), but the 5-year survival after surgery is only 27% -67%. Our guidelines have recommended neoadjuvant chemotherapy based on cisplatin as the first-line treatment for MIBC. Neoadjuvant chemotherapy can improve 5-year survival in MIBC patients. Now the chemotherapy of neoadjuvant chemotherapy, status quo and research directions are reviewed.